{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T13:50:12Z","timestamp":1773928212010,"version":"3.50.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100021778","name":"Agencia Nacional de Promoci\u00f3n de la Investigaci\u00f3n, el Desarrollo Tecnol\u00f3gico y la Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021778","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007880","name":"Johns Hopkins University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007880","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.vaccine.2025.128141","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T09:56:37Z","timestamp":1766224597000},"page":"128141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["COVID-19 vaccine production and the technological gap in the Global South: The cases of Argentina and Brazil"],"prefix":"10.1016","volume":"72","author":[{"given":"Maria J.","family":"Haro Sly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lautaro","family":"Zubeldia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.128141_bb0005","doi-asserted-by":"crossref","first-page":"03086","DOI":"10.7189\/jogh.11.03086","article-title":"International COVID-19 vaccine inequality amid the pandemic: perpetuating a global crisis?","volume":"11","author":"Tatar","year":"2021","journal-title":"J Glob Health"},{"issue":"1","key":"10.1016\/j.vaccine.2025.128141_bb0010","doi-asserted-by":"crossref","first-page":"195","DOI":"10.5195\/jwsr.2024.1173","article-title":"The world-system of vaccine distribution: Global inequalities and geopolitical conflicts during the COVID-19 pandemic","volume":"30","author":"K\u00f6ncke","year":"2024","journal-title":"J World-Syst Res"},{"key":"10.1016\/j.vaccine.2025.128141_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127377","article-title":"What are the key features of an equitable global vaccine strategy for the next pandemic?","volume":"61","author":"Fawole","year":"2025","journal-title":"Vaccine"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2025.128141_bb0020","article-title":"Acesso a vacinas no Brasil no contexto da din\u00e2mica global do complexo econ\u00f4mico-industrial da sa\u00fade","volume":"36","author":"Gadelha","year":"2020","journal-title":"Cad Saude Publica"},{"key":"10.1016\/j.vaccine.2025.128141_bb0025","series-title":"The top 5 vaccine companies by 2017 revenue","author":"Sagonowsky","year":"2018"},{"key":"10.1016\/j.vaccine.2025.128141_bb0030","series-title":"Global vaccine market report: a shared understanding for equitable access to vaccines","author":"World Health Organization","year":"2022"},{"issue":"2","key":"10.1016\/j.vaccine.2025.128141_bb0035","doi-asserted-by":"crossref","first-page":"494","DOI":"10.5195\/jwsr.2021.1049","article-title":"(2021) Covid-19 and semi-periphery: Argentina and the global vaccines research and development","volume":"27","author":"Blinder","year":"2021","journal-title":"J World-Syst Res"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2025.128141_bb0040","doi-asserted-by":"crossref","first-page":"B43","DOI":"10.1016\/j.vaccine.2012.11.079","article-title":"Vaccine development and deployment: opportunities and challenges in India","volume":"31","author":"Gupta","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.128141_bb0045","series-title":"Forum for Indian Science Diplomacy (FISD), Science Diplomacy Case Studies","article-title":"Indian vaccines industry addressing human health challenges","author":"Ghosh","year":"2019"},{"key":"10.1016\/j.vaccine.2025.128141_bb0050","author":"World Health Organization"},{"issue":"2","key":"10.1016\/j.vaccine.2025.128141_bb0055","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1017\/S0008197322000241","article-title":"Addressing vaccine inequity during the COVID-19 pandemic","volume":"81","author":"Thambisetty","year":"2022","journal-title":"Cambridge Law J."},{"key":"10.1016\/j.vaccine.2025.128141_bb0060","series-title":"Vaccine inequality: a deadly discrimination","author":"Ghosh","year":"2022"},{"key":"10.1016\/j.vaccine.2025.128141_bb0065","author":"Sagonowsky"},{"key":"10.1016\/j.vaccine.2025.128141_bb0070","series-title":"The top 20 pharma companies by 2023 revenue","author":"Dunleavy","year":"2024"},{"key":"10.1016\/j.vaccine.2025.128141_bb0075","author":"World Trade Organization"},{"issue":"1","key":"10.1016\/j.vaccine.2025.128141_bb0080","doi-asserted-by":"crossref","first-page":"35","DOI":"10.47692\/cadhistcienc.2007.v3.35696","article-title":"Bio-Manguinhos 30 anos: A trajet\u00f3ria de uma institui\u00e7\u00e3o p\u00fablica de ci\u00eancia e tecnologia","volume":"3","author":"Ponte","year":"2007","journal-title":"Cadernos de Hist\u00f3ria da Ci\u00eancia \u2013 Instituto Butantan"},{"issue":"3","key":"10.1016\/j.vaccine.2025.128141_bb0085","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/13505084211057259","article-title":"Overcoming enduring inequalities in global value chains?","volume":"29","author":"Paiva","year":"2022","journal-title":"Organization"},{"key":"10.1016\/j.vaccine.2025.128141_bb0090","series-title":"Brazil\u2019s role in the biopharmaceutical global value chain","author":"Reynolds","year":"2016"},{"key":"10.1016\/j.vaccine.2025.128141_bb0095","series-title":"La propiedad intelectual en el contexto del Acuerdo de la OMC sobre los ADPIC","article-title":"Protecci\u00f3n de patentes farmac\u00e9uticas en Brasil","author":"Oliveira","year":"2006"},{"issue":"S1","key":"10.1016\/j.vaccine.2025.128141_bb0100","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1017\/jme.2023.118","article-title":"The Brazilian Pharmaceutical Industry: actors, institutions, and policies","volume":"51","author":"Paranhos","year":"2023","journal-title":"J Law Med Ethics"},{"key":"10.1016\/j.vaccine.2025.128141_bb0105","series-title":"Produ\u00e7\u00e3o de insumo essencial para fabrica\u00e7\u00e3o de medicamentos no Brasil cai de 50% para 5% em 30 anos; entenda os riscos da redu\u00e7\u00e3o","author":"G1","year":"2024"},{"key":"10.1016\/j.vaccine.2025.128141_bb0110","author":"DATASUS"},{"issue":"9","key":"10.1016\/j.vaccine.2025.128141_bb0115","doi-asserted-by":"crossref","DOI":"10.1590\/0102-311x00056521","article-title":"Desafios globais para o acesso equitativo \u00e0 vacina\u00e7\u00e3o contra a COVID-19","volume":"37","author":"Souza","year":"2021","journal-title":"Cad Saude Publica"},{"key":"10.1016\/j.vaccine.2025.128141_bb0120","series-title":"Cassara Foundation seminar on \u201cLatin American experiences on the development of vaccines\u201d","article-title":"El proceso de transferencia de tecnolog\u00eda entre Astra Z\u00e9neca y Fiocruz","author":"Wolanski","year":"2022"},{"key":"10.1016\/j.vaccine.2025.128141_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.socscimed.2021.114093","article-title":"The politics of COVID-19 vaccination in middle-income countries: lessons from Brazil","volume":"281","author":"Fonseca","year":"2021","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.vaccine.2025.128141_bb0130","unstructured":"Butantan Institute. (n.d.). Nova f\u00e1brica do Butantan trar\u00e1 autossufici\u00eancia de IFA para vacinas contra COVID-19, zika, hepatite A e raiva ao pa\u00eds, diz Dimas Covas. https:\/\/butantan.gov.br\/noticias\/nova-fabrica-do-butantan-trara-autossuficiencia-de-ifa-para-vacinas-contra-covid-19-zika-hepatite-a-e-raiva-ao-pais-diz-dimas-covas."},{"key":"10.1016\/j.vaccine.2025.128141_bb0135","series-title":"Minist\u00e9rio da Sa\u00fade","author":"ANVISA","year":"2021"},{"key":"10.1016\/j.vaccine.2025.128141_bb0140","unstructured":"G1. (2024, August 23). Desenvolvimento da Butanvac \u00e9 suspenso ap\u00f3s vacina n\u00e3o atingir resultados nos estudos de fase 2. https:\/\/g1.globo.com\/saude\/noticia\/2024\/08\/23\/desenvolvimento-da-butanvac-e-suspenso-apos-vacina-nao-atingir-resultados-nos-estudos-de-fase-2.ghtml."},{"key":"10.1016\/j.vaccine.2025.128141_bb0145","author":"Butantan Institute"},{"key":"10.1016\/j.vaccine.2025.128141_bb0150","author":"ANVISA"},{"key":"10.1016\/j.vaccine.2025.128141_bb0155","series-title":"SpiN-Tec vaccine development update","author":"Melga\u00e7o","year":"2025"},{"key":"10.1016\/j.vaccine.2025.128141_bb0160","first-page":"2019","article-title":"Pol\u00edticas Tecnol\u00f3gica e Industrial en Contexto Semiperif\u00e9rico: la Producci\u00f3n P\u00fablica de Medicamentos en Argentina (2007-2015)","volume":"13","author":"Zubeldia","year":"2019","journal-title":"Universidad Nacional de Lan\u00fas, June"},{"issue":"54","key":"10.1016\/j.vaccine.2025.128141_bb0165","first-page":"1","article-title":"Des-aprendizaje y p\u00e9rdida de capacidades locales: El calendario nacional de vacunaci\u00f3n en Argentina","volume":"28","author":"Corval\u00e1n","year":"2017","journal-title":"Ciencia, Docencia y Tecnolog\u00eda"},{"issue":"168","key":"10.1016\/j.vaccine.2025.128141_bb0170","first-page":"14","article-title":"Producci\u00f3n nacional de vacunas: \u00bfUna meta imposible?","volume":"28","author":"Zubeld\u00eda","year":"2020","journal-title":"Ciencia Hoy"},{"key":"10.1016\/j.vaccine.2025.128141_bb0175","first-page":"253","article-title":"La brecha tecnol\u00f3gica regional y el caso de la producci\u00f3n de vacunas en Argentina y Brasil","volume":"30","author":"Zubeld\u00eda","year":"2023","journal-title":"Revista Tempo do Mundo."},{"key":"10.1016\/j.vaccine.2025.128141_bb0180","author":"PharmaBaires"},{"key":"10.1016\/j.vaccine.2025.128141_bb0185","series-title":"AstraZeneca har\u00e1 en Argentina 100 millones de vacunas extra, pero el Gobierno no pidi\u00f3 m\u00e1s","author":"Sigal","year":"2021"},{"key":"10.1016\/j.vaccine.2025.128141_bb0190","author":"Ministerio de Salud"},{"key":"10.1016\/j.vaccine.2025.128141_bb0195","series-title":"Desde adentro, c\u00f3mo ser\u00e1 la usina biotecnol\u00f3gica modelo de Richmond que fabricar\u00e1 vacunas y anticuerpos monoclonales para Argentina y la regi\u00f3n","author":"Blanco","year":"2023"},{"key":"10.1016\/j.vaccine.2025.128141_bb0200","author":"Roca"},{"key":"10.1016\/j.vaccine.2025.128141_bb0205","series-title":"Richmond producir\u00e1 en Argentina la vacuna china del COVID en vez de la rusa","author":"Quesada","year":"2022"},{"key":"10.1016\/j.vaccine.2025.128141_bb0210","series-title":"La ANMAT Autoriz\u00f3 a Laboratorios Richmond a Producir la Vacuna Contra el COVID-19 Convidecia","author":"INFOBAE","year":"2024"},{"key":"10.1016\/j.vaccine.2025.128141_bb0215","series-title":"Hugo Sigman vendi\u00f3 el 55% de su f\u00e1brica de vacunas para el COVID en 548 millones de d\u00f3lares al grupo alem\u00e1n Fresenius Kabi","author":"Blanco","year":"2022"},{"key":"10.1016\/j.vaccine.2025.128141_bb0220","series-title":"Est\u00e1 lista la primera vacuna de fabricaci\u00f3n argentina","author":"Ministry of Science, Technology, and Innovation of Argentina","year":"2023"},{"issue":"13","key":"10.1016\/j.vaccine.2025.128141_bb0225","doi-asserted-by":"crossref","first-page":"121","DOI":"10.24215\/26183188e121","article-title":"Siete ideas para potenciar la pol\u00edtica p\u00fablica a partir del caso de la vacuna ARVAC","volume":"7","author":"Peirano","year":"2024","journal-title":"Ciencia, Tecnolog\u00eda y Pol\u00edtica"},{"key":"10.1016\/j.vaccine.2025.128141_bb0230","series-title":"La OPS\/OMS reconoci\u00f3 a la ANMAT como autoridad reguladora de referencia regional de medicamentos","author":"Pan-American Health Organization","year":"2011"},{"key":"10.1016\/j.vaccine.2025.128141_bb0235","series-title":"Prequalified vaccines - prequalification of medical products IVDs, medicines, vaccines and immunization devices","author":"World Health Organization","year":"2025"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25014392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25014392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T10:29:23Z","timestamp":1773916163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25014392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":47,"alternative-id":["S0264410X25014392"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.128141","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 vaccine production and the technological gap in the Global South: The cases of Argentina and Brazil","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.128141","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"128141"}}